Altun O, Athlin S, Almuhayawi M, Strålin K, Özenci V
Division of Clinical Microbiology F 72, Karolinska Institutet, Karolinska University Hospital, Huddinge, 141 86, Stockholm, Sweden.
Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):579-85. doi: 10.1007/s10096-015-2573-9. Epub 2016 Jan 21.
Rapid identification of Streptococcus pneumoniae in blood culture (BC) bottles is important for early directed antimicrobial therapy in pneumococcal bacteraemia. We evaluated a new latex agglutination (LA) test on BC bottles, the ImmuLex™ S. pneumoniae Omni (Statens Serum Institut, Denmark), and compared the performance with the Slidex® pneumo-Kit (bioMérieux, France) and the Wellcogen™ S. pneumoniae (Remel, UK) LA tests, as well as the BinaxNOW® S. pneumoniae (Alere, USA) antigen test. The four tests were directly applied on 358 positive BC bottles with Gram-positive cocci in pairs or chains and on 15 negative bottles. Valid test results were recorded in all cases for ImmuLex and BinaxNOW and in 88.5 % (330/373) and 94.1 % (351/373) of cases for Slidex and Wellcogen, respectively. Based on bottles positive for S. pneumoniae by conventional methods, the sensitivity of ImmuLex was 99.6 %, similar to the other tests (range, 99.6-100 %). Based on bottles positive for non-pneumococcal pathogens, the specificity of ImmuLex was 82.6 %, in comparison to 97.6 % for Slidex (p < 0.01) and 85.4 % for Wellcogen (p = ns). The BinaxNOW test had a lower specificity (64.1 %) than any LA test (p < 0.01). On BC bottles positive for α-haemolytic streptococci, ImmuLex was positive in 12/67 (17.9 %) cases, Slidex in 2/59 (3.4 %) cases, Wellcogen in 11/64 (17.2 %) cases and BinaxNOW in 25/67 (37.3 %) cases. In conclusion, the ImmuLex test provides a valid and sensitive technique for the rapid detection of S. pneumoniae in BC bottles, similar to the other compared methods. However, the specificity was sub-optimal, since the test may cross-react with other Gram-positive bacteria.
快速鉴定血培养(BC)瓶中的肺炎链球菌对于肺炎球菌血症的早期针对性抗菌治疗至关重要。我们评估了一种用于BC瓶的新型乳胶凝集(LA)试验,即ImmuLex™肺炎链球菌全项检测(丹麦国家血清研究所),并将其性能与Slidex®肺炎试剂盒(法国生物梅里埃公司)、Wellcogen™肺炎链球菌检测(英国雷米尔公司)LA试验以及BinaxNOW®肺炎链球菌(美国阿莱公司)抗原检测进行比较。这四项检测直接应用于358个培养出成双或成链革兰氏阳性球菌的阳性BC瓶以及15个阴性瓶。ImmuLex和BinaxNOW在所有病例中均记录到有效检测结果,Slidex和Wellcogen分别在88.5%(330/373)和94.1%(351/373)的病例中记录到有效检测结果。基于传统方法检测出肺炎链球菌阳性的瓶,ImmuLex的敏感性为99.6%,与其他检测方法相似(范围为99.6% - 100%)。基于非肺炎球菌病原体阳性的瓶,ImmuLex的特异性为82.6%,相比之下,Slidex为97.6%(p < 0.01),Wellcogen为85.4%(p = 无显著差异)。BinaxNOW检测的特异性(64.1%)低于任何LA检测(p < 0.01)。在α - 溶血性链球菌阳性的BC瓶中,ImmuLex在12/67(17.9%)的病例中呈阳性,Slidex在2/59(3.4%)的病例中呈阳性,Wellcogen在11/64(17.2%)的病例中呈阳性以及BinaxNOW在25/67(37.3%)的病例中呈阳性。总之,ImmuLex检测为快速检测BC瓶中的肺炎链球菌提供了一种有效且灵敏的技术,与其他比较方法相似。然而,其特异性并不理想,因为该检测可能与其他革兰氏阳性菌发生交叉反应。